{
  "docId": "019de075-992f-724e-90ab-5f77d740e3ca",
  "docSlug": "2f355093e0d1610f6a0dd544c49160f7",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 33,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a potency spectrum chart to frame the problem of toxin evolution and a comparison table to highlight the competitive advantages of TATs.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-992f-724e-90ab-5f77d740e3ca/32",
  "deckHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca",
  "deckJsonHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca.json",
  "deckAnchorHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Increasing Potency (IC50, µM) spectrum with various drug names",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2e63b1d-19a1-41ae-b178-30c115e018c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "image",
      "text": "Multiple Mechanisms of Action of a TAT",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da1dd44e-33b6-4223-a9d0-c4c09696d1f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "quote",
      "text": "Radioconjugates are the next generation to the mainstays of cancer care. - BioWorld, April 11, 2022",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6550c66-97a2-4103-b271-c6d9ee1a7046",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.48
      },
      "kind": "table",
      "text": "TAT Advantages Over ADCs",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cfc38dd-634a-4960-aef7-4324b6b39334",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Targeted Alpha Therapy (TATs) as Next Generation Antibody Drug Conjugates (ADCs)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb51986b-534e-4377-ae5c-0ec9d219293a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Argument from Analogy",
      "slug": "argument-from-analogy",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "ae625183-8651-462d-ba1f-7f158124777e",
      "evidence": "The slide compares TATs to ADCs, using an analogy to explain the advantages of TATs.",
      "confidence": 0.7
    },
    {
      "name": "Metaphor & Analogy",
      "slug": "metaphor-analogy",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "101ffe41-42dc-458a-9a22-4e920ae725a1",
      "evidence": "The slide uses a comparison between TATs and ADCs, and also mentions 'next generation' implying a metaphorical progression.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "54eadf64-209c-43e9-a9a1-161589261dce",
      "evidence": "Comparison table of TAT vs ADC advantages",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}